Global Angular Cheilitis Treatment Market, By Diagnosis (Physical Examination, Others), Treatment (Antifungal, Antibiotics, Antiseptics, Steroid, Botulinum Toxin, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Angular Cheilitis Treatment Market Analysis and Size
Angular cheilitis is often related with oral thrush. Although candida is part of the normal oral flora, in around 60% of aged people with dentures overgrowth of this yeast is a problem. Successful treatment of angular cheilitis depends on the cause. For instance, topical therapy is likely to fail in nutritional deficiency. Angular cheilitis is most common in elderly and in denture wearers. It is also observed in people with HIV, Crohn’s disease or ulcerative colitis.
Data Bridge Market Research analyses a growth rate in the angular cheilitis treatment market in the forecast period 2023-2030. The expected CAGR of the angular cheilitis treatment market is around 7.50% in the forecast period. The market was valued at USD 3 billion in 2022, and it would grow to USD 5.35 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Angular Cheilitis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Symptom (Itching, Pain, Inflammation), Gender (Male, Female), Population at Risk (Smokers, Diabetic Patients, Patients Having Low BMI, Patients Suffering From Systemic Lupus Erythematosus, Others), Site (Fingers, Toes, Ear Lobes, Nose, Cheeks, Heels), Drug Type (Branded, Generic), Route of Administration (Oral, Topical, Others),End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc. (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Zydus Group (India), Lupin (India), Bayer AG (Germany), Torrent Pharmaceuticals Ltd (India), Cadila Pharmaceuticals (India), Lupin (India), Aurobindo Pharma (India), Hikma Pharmaceuticals PLC (U.K.), Alkem Labs Ltd (India), Cosette Pharmaceuticals (U.K.), GSK Plc. (U.K.), Amneal Pharmaceutical Inc.(U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Ltd.(India), Perrigo Company plc.(Ireland.), Akorn Operating Company LLC.(India)
|
|
Market Opportunities
|
|
Market Definition
Angular cheilitis is the type of infection or inflammation which causes red, swollen patches in the corners of the lips. It is also known as perleche and angular stomatitis. The primary symptoms are bleeding, blistered, cracked lips, redness, scaly, pain in the lips and others. Fungal infection is the most common cause of angular cheilitis, generally caused by a type of yeast called Candida. Angular cheilitis can also be caused by the deficiency in riboflavin (vitamin B2).
Angular Cheilitis Treatment Market Dynamics
Drivers
- Prevalence in Angular Cheilitis
Angular cheilitis is a fairly common problem, that results in around 0.7% of the population. It occurs most often in people in their 30s to 60s, and is also comparatively common in children. Another study in 2014 stated that there was a prevalence of 2.5 of herpes labialis and 1.9 prevalence per 1,000 persons of angular chelitis. Thus, the incidence rate is increasing the market growth.
- Increase in Treatment Methods
Successful treatment of angular cheilitis depends on the cause. The patient can be treated with topical therapy, miconazole oral gel, antifungal agents such as nystatin and amphotericin. Thus, it helps in the market growth.
Opportunities
- Increasing Diabetes Cases
The number of people with diabetes increased from 108 million in 1980 to 422 million in 2014. Incidence has been rising more rapidly in low- and middle-income countries than in high-income countries. In 2019, diabetes and kidney disease because of diabetes caused an estimated 2 million deaths. It is found that people suffering from diabetes suffer from fungal infections very easily, such as angular cheilitis. Extra glucose in the body can create a breeding ground for fungus. Additionally, diabetes also weakens your immune system, which makes it harder for the body to fight off infection.
- Increasing Demand for Retail Pharmacies
Several angular cheilitis therapeutics are delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries creates many opportunities for market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Limited Studies and Surveys
There are very few studies and surveys that are hindering the growth of the market. Only a limited amount of data are available concerning the clinical and research studies. A few studies mainly focused on groups from a single hospital where only a limited number of patients were observed. Thus, this hinders the growth of the market.
- High Cost
The huge expenditure associated with angular cheilitis medications hampers the market growth. This disease involves treatment with various antifungal medications, botulinum toxin injections, and steroids. This acts as a major limitation for the market.
This angular cheilitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the angular cheilitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Angular Cheilitis Treatment Market Scope
The angular cheilitis treatment market is segmented on the basis of diagnosis, treatment, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Physical Examination
- Others
Treatment
- Antifungal
- Antibiotics
- Antiseptics
- Steroid
- Botulinum Toxin
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Angular Cheilitis Treatment Market Regional Analysis/Insights
The angular cheilitis treatment market is analyzed and market size insights and trends are provided by diagnosis, treatment, end-user and distribution channel as referenced above.
The major countries covered in the angular cheilitis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for the angular cheilitis treatment market throughout the forecasted period due to the presence of high healthcare expenditure and research & development.
Asia-Pacific dominates the market due to increased technological advancement, growing healthcare expenditure, and rising awareness program.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Angular Cheilitis Treatment Market Share Analysis
The angular cheilitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to angular cheilitis treatment market
Key players operating in the angular cheilitis treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Bayer AG (Germany)
- Torrent Pharmaceuticals Ltd (India)
- Cadila Pharmaceuticals (India)
- Piramal Enterprises Ltd. (India)
- Lupin (India), Lannett (U.S.)
- Aurobindo Pharma (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Alkem Labs Ltd (India)
- Cosette Pharmaceuticals (U.K.)
- GSK Plc. (U.K.)
- Amneal Pharmaceutical Inc.(U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Dr. Reddy's Laboratories (India)
- Perrigo Company plc.(Ireland.)
- Akorn Operating Company LLC.(India)
SKU-